Literature DB >> 12653751

Scleromyxoedema-like changes in four renal dialysis patients.

V Hubbard1, A Davenport, M Jarmulowicz, M Rustin.   

Abstract

We describe four renal dialysis patients from our hospital who, over a 6-month period, developed erythematous, thickened, indurated dermal plaques. The plaques were limited to the limbs and in three patients there were associated flexion contractures. The clinical features most resembled scleromyxoedema. All patients had previously received at least one renal transplant. Histopathology of the plaques showed features of scleromyxoedema in two patients, whereas the other two showed a different picture, more suggestive of a morphoea-like process. There are important differences between our patients and classical scleromyxoedema. All four patients had normal immunoglobulins and no paraprotein was detected. Almost all cases of classical scleromyxoedema are associated with an IgGlambda paraproteinaemia. We have not yet identified an underlying cause for this cluster of cases in our hospital. It is possible that the skin changes seen may have been precipitated by an environmental agent, such as in 'toxic oil syndrome' and vinyl chloride-induced scleroderma. We discuss the differences between our patients and those with scleromyxoedema, localized or generalized morphoea and environmentally induced scleroderma. We feel that our patients show a constellation of features similar, but not identical, to scleromyxoedema. There has been only one previous report of similar patients. We believe this to be a new and distinct phenomenon.

Entities:  

Mesh:

Year:  2003        PMID: 12653751     DOI: 10.1046/j.1365-2133.2003.05181.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  11 in total

Review 1.  Nephrogenic systemic fibrosis in liver disease: a systematic review.

Authors:  Sameer M Mazhar; Masoud Shiehmorteza; Chad A Kohl; Michael S Middleton; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2009-12       Impact factor: 4.813

2.  Nephrogenic fibrosing dermopathy in children.

Authors:  Ari Auron; Lei Shao; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2006-07-05       Impact factor: 3.714

Review 3.  Nephrogenic systemic fibrosis: an update.

Authors:  Shawn E Cowper; Philip J Boyer
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

4.  [Nephrogenic systemic fibrosis].

Authors:  W Samtleben
Journal:  Radiologe       Date:  2007-09       Impact factor: 0.635

5.  Nephrogenic fibrosing dermopathy in pediatric patients.

Authors:  Sima M Jain; Stanton Wesson; Ashraf Hassanein; Erica Canova; Miranda Hoy; Robert S Fennell; Vikas R Dharnidharka
Journal:  Pediatr Nephrol       Date:  2004-02-10       Impact factor: 3.714

Review 6.  Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents.

Authors:  Jeffrey G Penfield
Journal:  Pediatr Nephrol       Date:  2008-06-10       Impact factor: 3.714

Review 7.  Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity.

Authors:  Derrick J Todd; Jonathan Kay
Journal:  Curr Rheumatol Rep       Date:  2008-07       Impact factor: 4.592

Review 8.  Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature.

Authors:  Fabian A Mendoza; Carol M Artlett; Nora Sandorfi; Kevin Latinis; Sonsoles Piera-Velazquez; Sergio A Jimenez
Journal:  Semin Arthritis Rheum       Date:  2006-02       Impact factor: 5.532

9.  Revisiting the risks of MRI with Gadolinium based contrast agents-review of literature and guidelines.

Authors:  Aurang Z Khawaja; Deirdre B Cassidy; Julien Al Shakarchi; Damian G McGrogan; Nicholas G Inston; Robert G Jones
Journal:  Insights Imaging       Date:  2015-08-08

10.  Understanding nephrogenic systemic fibrosis.

Authors:  Tushar Chopra; Kiran Kandukurti; Silvi Shah; Raheel Ahmed; Mandip Panesar
Journal:  Int J Nephrol       Date:  2012-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.